Targeted LNPs: From Ligand Conjugation & Preclinical Screening To Process Optimization And Scale-Up

Targeted lipid nanoparticles (tLNPs) offer a promising route to deliver nucleic acid payloads to specific cells and tissues beyond the liver. Achieving that precision requires the careful selection and covalent conjugation of targeting ligands, including full-length antibodies, antibody fragments, VHH nanobodies, and peptides. It also depends on analytical methods capable of evaluating critical quality attributes throughout development. Follow an integrated workflow spanning early conjugation screening, lead identification, analytical characterization, downstream purification, and process optimization. Practical insights into scalable manufacturing demonstrate how promising candidates can progress from initial studies toward larger-scale production.

Learn how coordinated expertise across chemistry, analytics, purification, and manufacturing can help address common development challenges and accelerate the path to a robust tLNP process.